Key Findings
The Europe intrauterine device market is predicted to reach $XX million by the end of 2027, rising from $XX million in 2018. This growth can be further quantified to the estimated value of 3.43% CAGR of market growth over the forecast period of 2019-2027. The European region has been stressing on health care providers (HCPs) in Europe to utilize model as a training and educational device to encourage increased adoption of IUDs in the region.

Market Insights
The obstacles to increased IUD uptake across Europe vary widely, simulation training shows great potential as a means of justifying practitioner and, in turn, patient concerns over pain from or difficulty of IUD insertion, side effects or complications from IUD usage thereby increasing the demand for ICD devices in the market.

The Europe region comprises of United Kingdom, Germany, France, Italy, Spain and the Rest of Europe. The Spain segment dominated the Europe segment with a CAGR of XX% owing to the increased demand for contraceptive devices in the region thereby fueling the growth of the market in the forecast period.

Competitive Insights
HLL LifeCare Ltd., SMB Corporation, Pfizer, Okamoto Industries Inc., Allergan PLC, Bayers AG, Medisafe Distribution Inc., Egemen International, Krishco Medical Products Pvt. Ltd., Meril Life Sciences Pvt. Ltd., Medicines360, OCON Medical Ltd., Teva Pharmaceutical Industries Limited, Merck & Co., Pregna, Mona Lisa N.V., Trimedic Supply Network Ltd., DKT International, Melbea, and Zhejiang Daji Medical Instruments Co., Ltd. are few of the established companies in the market that are mentioned in the report.